Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
Banner MD Anderson, Gilbert, Arizona Stanford Cancer Institute, Stanford, California Emory Winchip Cancer Center, Atlanta, Georgia University of Kansas Clinical Research Center, Westwood, Kansas Dana Farber Cancer Institute, Boston, Massachusetts Karmanos Cancer Institute, Detroit, Michigan START Midwest, Grand Rapids, Michigan University of Rochester Medical Center, Rochester, New York University of North Carolina Hospitals at Hillsborough, Chapel Hill, North Carolina Huntsman Cancer Center Institute University of Utah, Salt Lake City, Utah Fred Hutchinson Cancer Center, Seattle, Washington